911637-19-9,MFCD19443742
Catalog No.:AA00H0FH

911637-19-9 | Gemigliptin

Pack Size
Purity
Availability
Price(USD)
Quantity
  
2mg
1 week  
$96.00   $68.00
- +
5mg
1 week  
$120.00   $84.00
- +
10mg
1 week  
$159.00   $112.00
- +
25mg
1 week  
$239.00   $168.00
- +
50mg
1 week  
$368.00   $258.00
- +
100mg
1 week  
$547.00   $383.00
- +
500mg
1 week  
$1,165.00   $816.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00H0FH
Chemical Name:
Gemigliptin
CAS Number:
911637-19-9
Molecular Formula:
C18H19F8N5O2
Molecular Weight:
489.3630
MDL Number:
MFCD19443742
SMILES:
N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F
Properties
Computed Properties
 
Complexity:
746  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
13  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
4  
XLogP3:
0.7  

Literature

Title: Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.

Journal: Clinical therapeutics 20120501

Title: Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.

Journal: International journal of clinical pharmacology and therapeutics 20120101

Title: A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism 20101201

Title: Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Journal: Clinical therapeutics 20081001

Title: Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102.

Title: Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 911637-19-9
Tags:911637-19-9 Molecular Formula|911637-19-9 MDL|911637-19-9 SMILES|911637-19-9 Gemigliptin
Catalog No.: AA00H0FH
911637-19-9,MFCD19443742
911637-19-9 | Gemigliptin
Pack Size: 2mg
Purity:
1 week
$96.00 $68.00
Pack Size: 5mg
Purity:
1 week
$120.00 $84.00
Pack Size: 10mg
Purity:
1 week
$159.00 $112.00
Pack Size: 25mg
Purity:
1 week
$239.00 $168.00
Pack Size: 50mg
Purity:
1 week
$368.00 $258.00
Pack Size: 100mg
Purity:
1 week
$547.00 $383.00
Pack Size: 500mg
Purity:
1 week
$1,165.00 $816.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00H0FH
Chemical Name: Gemigliptin
CAS Number: 911637-19-9
Molecular Formula: C18H19F8N5O2
Molecular Weight: 489.3630
MDL Number: MFCD19443742
SMILES: N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F
Properties
Complexity: 746  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 1  
Heavy Atom Count: 33  
Hydrogen Bond Acceptor Count: 13  
Hydrogen Bond Donor Count: 1  
Rotatable Bond Count: 4  
XLogP3: 0.7  
Literature fold

Title: Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.

Journal: Clinical therapeutics20120501

Title: Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.

Journal: International journal of clinical pharmacology and therapeutics20120101

Title: A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism20101201

Title: Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Journal: Clinical therapeutics20081001

Title: Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102.

Title: Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64.

Building Blocks More >
874-46-4
874-46-4
[1,2,4]Triazolo[1,5-a]pyridin-2-amine
AA00H0WS | MFCD11846603
91908-29-1
91908-29-1
N,N-DIETHYLINDOLINE-5-SULFONAMIDE
AA00H18X | MFCD07687991
942-97-2
942-97-2
4-Methoxy-2-methylphenylacetic acid
AA00H1K3 | MFCD02664778
882760-46-5
882760-46-5
2-[(2,6-Dibromo-4-methylphenyl)amino]acetohydrazide
AA00H1US | MFCD00448181
886361-38-2
886361-38-2
Methyl 2-amino-5-(2-fluorophenyl)-1,3-thiazole-4-carboxylate
AA00H1YR | MFCD06200924
899897-20-2
899897-20-2
5-Bromo-2-methylthiazole-4-carboxylic acid
AA00H2I9 | MFCD18821105
91550-08-2
91550-08-2
(S)-tert-Butyl 2-acetylpyrrolidine-1-carboxylate
AA00H2X0 | MFCD11975893
891785-18-5
891785-18-5
3-(Benzyloxy)-5-bromo-2-chloropyridine
AA00H395 | MFCD26403034
887481-28-9
887481-28-9
1-(4-Methyloxan-4-yl)ethan-1-one
AA00H465 | MFCD24712853
92310-23-1
92310-23-1
ethyl 4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylate
AA00H542 | MFCD09743296
Submit
© 2017 AA BLOCKS, INC. All rights reserved.